Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Zhejiang University

Reviewed by TrialFinderData Editorial Team · Updated

8 clinical trials · 8 recruiting · OTHER

Zhejiang University has 8 clinical trials registered on ClinicalTrials.gov, with 8 actively recruiting participants. The trials listed below cover 13 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Zhejiang University\'s Trial Portfolio

Zhejiang University is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

8 of Zhejiang University's 8 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Zhejiang University's research footprint spans Systemic Lupus Erythematosus (2 trials), tumor-of-pancreas (1), and surgical-blood-loss (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Early Phase 1 is the largest single phase in Zhejiang University's portfolio at 38% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Zhejiang University

RECRUITINGNCT06164769

Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery

Pancreatic enucleation could preserve more healthy pancreatic tissues and functions with a low recurrence risk. However, conventional enucleation can cause significant...

Sponsor: Zhejiang UniversityEnrolling: 301 location
Tumor of PancreasSurgical Blood Loss
RECRUITINGPhase 2NCT06770452

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642...

Sponsor: Zhejiang UniversityEnrolling: 1332 locations
Metastatic Pancreatic Carcinoma
RECRUITINGPhase 2NCT06770439

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

This study is a phase II study to evaluate the safety, tolerability and efficacy of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer, including Part1...

Sponsor: Zhejiang UniversityEnrolling: 642 locations
Advanced Pancreatic Cancers
RECRUITINGPhase 1NCT06027853

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients...

Sponsor: Zhejiang UniversityEnrolling: 241 location
AML, Adult
RECRUITINGNCT07359586

Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia

This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine...

Sponsor: Zhejiang UniversityEnrolling: 12002 locations
Gastric CancerHepatic CarcinomaPulmonary Carcinoma+3
RECRUITINGEarly Phase 1NCT06920433

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus. This study aims to evaluate the safety...

Sponsor: Zhejiang UniversityEnrolling: 181 location
Systemic Lupus Erythematosus
RECRUITINGEarly Phase 1NCT06711146

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active...

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Moderate to Severe Active Systemic Lupus Erythematosus

Sponsor: Zhejiang UniversityEnrolling: 361 location
Systemic Lupus Erythematosus
RECRUITINGEarly Phase 1NCT06082050

Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy

This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin...

Sponsor: Zhejiang UniversityEnrolling: 71 location
Transthyroxin Amyloidosis Cardiomyopathy

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Zhejiang University have on ClinicalTrials.gov?

Zhejiang University has 8 clinical trials registered on the federal ClinicalTrials.gov registry, of which 8 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Zhejiang University study?

Zhejiang University's registered trials cover 13 conditions on ClinicalTrials.gov, led by Systemic Lupus Erythematosus (2 trials), tumor-of-pancreas (1 trial), surgical-blood-loss (1 trial), Metastatic Pancreatic Carcinoma (1 trial), Advanced Pancreatic Cancers (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Zhejiang University clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 8 trials tracked for Zhejiang University.